Bicycle Therapeutics plc (NASDAQ:BCYC) CFO Alethia Young Sells 1,395 Shares

Bicycle Therapeutics plc (NASDAQ:BCYC) CFO Alethia Young sold 1,395 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $19,655.55. Following the completion of the transaction, the chief financial officer now directly owns 45,605 shares of the company’s stock, valued at approximately $642,574.45. This represents a 2.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Bicycle Therapeutics Price Performance

Shares of BCYC stock opened at $14.88 on Tuesday. The business has a 50-day moving average of $19.27 and a 200 day moving average of $21.86. Bicycle Therapeutics plc has a 1-year low of $12.17 and a 1-year high of $28.67. The stock has a market capitalization of $1.03 billion, a PE ratio of -4.52 and a beta of 0.92.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm had revenue of $2.68 million during the quarter, compared to analyst estimates of $6.82 million. During the same quarter in the prior year, the firm posted ($1.26) earnings per share. The business’s quarterly revenue was down 50.0% compared to the same quarter last year. Analysts anticipate that Bicycle Therapeutics plc will post -3.05 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on BCYC shares. JMP Securities cut their target price on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research report on Wednesday, December 18th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. Stephens began coverage on Bicycle Therapeutics in a research report on Friday, November 8th. They set an “equal weight” rating and a $25.00 price objective on the stock. B. Riley dropped their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, HC Wainwright cut their target price on Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating for the company in a research note on Monday, December 16th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.25.

Institutional Investors Weigh In On Bicycle Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. FMR LLC bought a new position in shares of Bicycle Therapeutics during the third quarter valued at about $3,406,000. TD Asset Management Inc increased its holdings in Bicycle Therapeutics by 76.7% during the 2nd quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock valued at $1,967,000 after purchasing an additional 42,200 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Bicycle Therapeutics by 33.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company’s stock valued at $2,935,000 after purchasing an additional 32,313 shares during the period. Principal Financial Group Inc. bought a new position in Bicycle Therapeutics during the 3rd quarter valued at approximately $10,028,000. Finally, State Street Corp lifted its holdings in Bicycle Therapeutics by 233.5% in the 3rd quarter. State Street Corp now owns 86,271 shares of the company’s stock worth $1,952,000 after buying an additional 60,399 shares during the period. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.